Analysts expect Iovance Biotherapeutics to report an earnings per share (EPS) of $-0.30.
Investors in Iovance Biotherapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Earnings Track Record
During the last quarter, the company reported an EPS beat by $0.01, leading to a 24.94% increase in the share price on the subsequent day.
Here's a look at Iovance Biotherapeutics's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
-0.35
-0.42
-0.43
-0.45
EPS Actual
-0.34
-0.42
-0.45
-0.46
Price Change %
25.0%
-18.0%
-9.0%
-3.0%
Stock Performance
Shares of Iovance Biotherapeutics were trading at $11.66 as of November 05. Over the last 52-week period, shares are up 204.56%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Analyst Views on Iovance Biotherapeutics
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Iovance Biotherapeutics.
A total of 3 analyst ratings have been received for Iovance Biotherapeutics, with the consensus rating being Buy. The average one-year price target stands at $27.0, suggesting a potential 131.56% upside.
Analyzing Ratings Among ...
